A Look Back at How Well Interventional Treatments Work for Bronchopleural Fistulas in Patients With Lung Metastases From Osteosarcoma

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* The patient was diagnosed with osteosarcoma by histology or cytology, and pulmonary metastasis with bronchopleural fistula (BPF) was confirmed by imaging (CT/PET-CT);
* Present with clinical symptoms associated with BPF (e.g., hemoptysis, pneumothorax, persistent pleural infection, etc.) that are ineffective or poorly responded to traditional treatments (pharmacologic hemostasis, closed thoracic drainage);
* Angiographically confirmed abnormal bronchial or intercostal artery blood supply to the fistula and anatomy suitable for NBCA with coil embolization;
* Age ≤75 years, ECOG performance status ≤2, and predicted survival ≥3 months.
* Coagulation function was basically normal.

Exclusion Criteria:

* Had a history of severe allergy or contraindication to NBCA glue, iodine contrast agent or coil materials;
* Severe cardiopulmonary dysfunction (e.g., NYHA class III-IV, FEV1 \< 30% predicted, uncontrolled pulmonary hypertension);
* Angiographic abnormalities of the target vessel anatomy (e.g., severe tortuosity, stenosis, or occlusion) prevented the catheter from safely reaching the target embolization site;
* Active systemic infection (e.g., sepsis, active tuberculosis) or uncontrolled local infection;
* Other major organ failure (Child-Pugh C cirrhosis, eGFR \< 30 mL/min/1.73m²);
* Women who are pregnant or lactating or plan to become pregnant during the study.